PH Treatments: What's on the Horizon
With the recent FDA approval of three new treatments in just a few months, the past year has brought exciting advances in PH research! Join Dr. Michael McGoon of the Mayo Clinic for a presentation on the current treatments available for PH, as well as new treatments in the pipeline.
Rare Opportunity to Impact FDA Decisions
10903 New Hampshire Ave.Silver Spring, MD 20993 (FDA Campus)
On May 13, the FDA will host an unusual public meeting about pulmonary arterial hypertension. For the first time, PAH patients are invited to share their thoughts on what it means to live with the disease and what they would like to see in a perfect treatment.
Learn More »
06.20.2014 - 06.22.2014
2014 PHA's International PH Conference and Scientific Sessions
JW Marriott Indianapolis
Indianapolis, Ind., U.S.A.
The Alfred P. Fishman Symposium: New Treatment Approaches to Pulmonary Hypertension
Sonesta Hotel Philadelphia
Philadelphia, PA 19103
05.16.2014 - 05.21.2014
ATS Annual Conference
San Diego, CA
The American Thoracic Society’s International Conference features the latest scientific and medical advances in pulmonary, critical care, and sleep medicine. With more than 400 sessions, 800 speakers and, 5,700 research abstracts and case studies, the conference is recognized as the leader in the field.
Learn More »
Pulmonary Hypertension Conference
Brent House Conference Center,
New Orleans, LA
Sponsored by the Ochsner Clinic Foundation
07.14.2014 - 07.15.2014
1st Annual Drug Discovery and Development for Pulmonary Hypertension Symposium
Doubletree Hotel Bethesda
Bethesda, MD 20814
The Drug Discovery and Development for Pulmonary Hypertension Symposium will be held annually
each summer to bring leading scientists in the fields of pulmonary vascular disease, right heart failure,
and clinical trial designs together with the pharmaceutical industry and regulatory authorities to help
identify the most promising treatments for future development. For this initial meeting we have
assembled a faculty of exceptional achievements and expertise, and have chosen topics in areas that will
influence the development of therapies immediately. Each topic will be critically reviewed by an expert
panel, and open dialogue will allow your voice to be heard.
Alfred P. Fishman Symposium: New Treatment Approaches to Pulmonary Hypertension
Sonesta Hotel Philadelphia 1800 Market Street Philadelphia, PA 19103
A CME-Certified Event: Saturday, April 26, 2014. In conjunction with: Hospital of the University of Pennsylvania Department of Nursing Education, Innovation and Professional Development.
While lung transplantation was the first therapeutic option available for patients with pulmonary hypertension (and continues to be the ultimate treatment for patients who do not respond to other interventions), the last twenty years have seen a surge in research and development of novel medical therapies.
There are 11 FDA-approved medical therapies for pulmonary arterial hypertension (PAH) and chronic thromboembolic disease. While these treatments have traditionally been classified by the pathophysiologic pathways they target, their clinical effects are complex in terms of patient response, side effects, and dose titration. In addition, new disease pathways have been targeted in recent preclinical and early phase studies, suggesting that more therapies are on the horizon.
06.02.2014 - 06.03.2014
International CTEPH Conference 2014 Paris
Institut des Cordeliers, Paris, France
The International CTEPH Association (ICA) will held in June 2014 an international Conference fully dedicated to Chronic Thromboembolic Pulmonary Hypertension (CTEPH).